Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Acute promyelocytic leukemia: preventing early complications and late toxicities. Hematology Am Soc Hematol Educ Program 2016 Dec 02;2016(1):10-15

Date

12/04/2016

Pubmed ID

27913456

Pubmed Central ID

PMC6142484

DOI

10.1182/asheducation-2016.1.10

Scopus ID

2-s2.0-85021848968   28 Citations

Abstract

Acute promyelocytic leukemia (APL) is a unique subtype of acute myeloid leukemia (AML), which presents with a distinct coagulopathy. Therapeutic advances have made APL one of the true success stories in oncology, transforming this once lethal disease into the most curable form of AML. For many patients, cure will now be achieved without the use of chemotherapy. It is hoped that limiting chemotherapy will reduce mortality even further, particularly among more vulnerable older adults whose survival lagged behind that of younger patients. It should be noted that early death persists in patients with APL and continues to negatively affect survival. Further, among survivors treated with chemotherapy or even arsenic trioxide (ATO), there remains the potential for long-term toxicities that must be monitored. Understanding the management of these issues is an important complement to ensure maximal survival for patients with APL.

Author List

Abedin S, Altman JK

Author

Sameem Abedin MD Assistant Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Adult
Age Factors
Arsenicals
Disease-Free Survival
Humans
Leukemia, Promyelocytic, Acute
Oxides
Survival Rate